Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
the industry analysis specialist, has released its new reports” Disease Therapeutics - Global Drug
Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis
on the global therapeutics market. It provides comprehensive market information, highlighting the treatment guidelines and identifying and analyzing the key trends shaping and driving the global market. It analyzes treatment usage patterns and provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the market leaders. The report provides valuable insights into the pipeline products and quantifies the unmet need within the global PD therapeutics market and as well as in the individual markets of the US and the top five countries in Europe, highlighting opportunities for future players.
Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China
Graves’ Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019 Feb 2012
The report provides information on the key drivers and challenges of the Graves Disease Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Graves Disease Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. The report provides information on the key drivers and challenges of the Graves Disease Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Graves Disease Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Graves Disease Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Graves Disease Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Graves Disease Therapeutics market
Market Research Reports Distributor - Aarkstore.com have vast database on market research reports, company financials, company profiles, SWOT analysis, company report, company statistics, strategy review, industry report, industry research to provide excellent and innovative service to our report buyers.
Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020 Feb 2012
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
In 2011, the global Parkinson’s Disease (PD) therapeutics market, which includes the key markets of the US, Japan, Germany, the UK, France, Italy, Spain, Brazil, China, India and Russia was estimated to be worth $2,992m. During the period 2002-2011, the global PD therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 5.8%. GlobalData analysis shows that the market size was primarily driven by two key parameters: the increase in PD prevalence due to the increase in the aging population in the 11 key markets and the increasing cost of therapy. In 2011, the market registered a decline in the market valuations due to the entry of generics for Mirapex (pramipexole) and higher preference for generic ropinirole.The global PD therapeutics market is primarily served by levodopa, dopamine agonists, Monoamine Oxidase Inhibitors (MAO-BI) and Catechol-O-Methyltransferase (COMT) inhibitors. The market is dominated by branded products such as Boehringer Ingelheim’s
Mirapex/Mirapexin/Sifrol/MirapexER/MirapexinER (pramipexole), GlaxoSmithKline’s (GSK)
Requip/RequipXL(ropinirole),Orion/Novartis’ Stalevo/Comtan (carbidopa/levodopa/entacapone) and Teva/Lundbeck’s Azilect/Agilect (rasagiline). In addition, a large number of generics are also available in this market. The global PD therapeutics market is expected to grow at a modest CAGR of 2.2% and is forecast to reach $3,650m by 2020. The modest growth rate has been attributed to patent expiries of the major drugs, the subsequent entry of generics and the weak late stage developmental pipeline.
Gaucher’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Jan 2012
Fabrys Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Dec 2011 Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Dec 2011 Fabry’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Dec 2011 Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Dec 2011 Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018 Nov 2011
Periodontal Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Nov 2011 Rare Disease Therapeutics, Inc.-Therapeutic Competitors Report Mar 2011 Rare Disease Therapeutics, Inc.-Detailed Product Pipeline Jan 2011
Lyme disease Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Dec 2010 Rare Disease Therapeutics, Inc.-Company Report April 2010